Hexima (HXL.AX) Stock Price

Hexima Price

CLOSED
0.05
​
Market closed

Over the last 17 years Hexima grew revenue by 12.4% annually, reaching 1.48 M AUD. For Hexima, the net margin of -129.2% is up versus -363.0% a few years ago.

Hexima stock price

Access this data via the Eulerpool API

Hexima business model & stock analysis

Hexima Ltd. is a biotechnology company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2020-12-01. The firm is engaged in the research and development of plant defensin peptides for applications in human therapeutics. Its lead drug candidate is the plant defensin, pezadeftide, developed for the treatment of fungal nail infections. The firm is conducting phase II clinical trial testing pezadeftide as a treatment for onychomycosis. Its Antifungal Plant Defensin Technology platform is engaged in identifying several plant peptides with potent antifungal activity against a broad range of human fungal pathogens. The company is also investigating the application of its plant defensin technology to other human fungal diseases.

Frequently asked questions about Hexima

5 analysts currently rate the Hexima stock: 4 recommend buying, 1 holding and 0 selling.

Converted at the current exchange rate, the Hexima share trades at 0.03 EUR (0.05 AUD).

The revenue cannot currently be calculated for Hexima.

The profit cannot currently be calculated for Hexima.

The P/E ratio cannot be calculated for Hexima at the moment.

The P/S cannot be calculated for Hexima currently.

The Eulerpool Quality Score for Hexima is 1/10.

The ISIN of Hexima is AU0000111932. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Hexima is HXL.AX. The ticker symbol is used to trade Hexima shares on the stock exchange.

Fair ValueTerminal
0.04 AUD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Australia
Currency
AUD
Initial public offering
Dec 1, 2020
ISIN
AU0000111932
Cusip
Q4562D113
Market capitalization
8.69 M AUDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
5.73
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-33.22 %
Last updated Oct 10, 2026, 10:39 PM

Hexima Peer Group

Hexima FIGI

HXL:AU · BBG000R1TVK5HXL:AT · BBG000R1TW69HXL:AH · BBG002GT8GZ2

All fundamentals and in-depth analysis of Hexima

Our stock analysis for Hexima stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Hexima. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.